Micot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke

Bulletin Express07-03

Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute ischemic stroke (AIS), following the successful enrolment of the first patient.

\n\nThe trial is structured in two sequential parts. Part 1 is a multicentre study designed to assess the safety, preliminary efficacy and pharmacokinetic profile of MT1002 in AIS patients. Part 2 will advance to a multicentre, randomised, standard-of-care–controlled design, focusing on broader safety and efficacy metrics. The initial patient enrolment announced pertains to Part 1.

\n\nMarket data underscore the therapeutic need: AIS represents approximately 69.60%–72.80% of newly diagnosed strokes in China, according to “Advances in the Treatment of Acute Ischemic Stroke (2025)”. Pharnexcloud estimates place the Chinese market for acute-phase ischemic stroke therapies consistently above RMB10 billion in recent years, reaching RMB12.90 billion in 2023.

\n\nThe company positions MT1002 as a potential entrant into this sizeable market, with the ongoing clinical study intended to generate key safety and efficacy data to guide further development steps.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102266225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102266225","market":"us","top_or_hot":-1,"title":"Micot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke","media":"Bulletin Express","content":"<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute ischemic stroke (AIS), following the successful enrolment of the first patient.</p>\n<p>\\n\\nThe trial is structured in two sequential parts. Part 1 is a multicentre study designed to assess the safety, preliminary efficacy and pharmacokinetic profile of MT1002 in AIS patients. Part 2 will advance to a multicentre, randomised, standard-of-care–controlled design, focusing on broader safety and efficacy metrics. The initial patient enrolment announced pertains to Part 1.</p>\n<p>\\n\\nMarket data underscore the therapeutic need: AIS represents approximately 69.60%–72.80% of newly diagnosed strokes in China, according to “Advances in the Treatment of Acute Ischemic Stroke (2025)”. Pharnexcloud estimates place the Chinese market for acute-phase ischemic stroke therapies consistently above RMB10 billion in recent years, reaching RMB12.90 billion in 2023.</p>\n<p>\\n\\nThe company positions MT1002 as a potential entrant into this sizeable market, with the ongoing clinical study intended to generate key safety and efficacy data to guide further development steps.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Micot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute ischemic stroke (AIS), following the successful enrolment of the first patient.</p>\n<p>\\n\\nThe trial is structured in two sequential parts. Part 1 is a multicentre study designed to assess the safety, preliminary efficacy and pharmacokinetic profile of MT1002 in AIS patients. Part 2 will advance to a multicentre, randomised, standard-of-care–controlled design, focusing on broader safety and efficacy metrics. The initial patient enrolment announced pertains to Part 1.</p>\n<p>\\n\\nMarket data underscore the therapeutic need: AIS represents approximately 69.60%–72.80% of newly diagnosed strokes in China, according to “Advances in the Treatment of Acute Ischemic Stroke (2025)”. Pharnexcloud estimates place the Chinese market for acute-phase ischemic stroke therapies consistently above RMB10 billion in recent years, reaching RMB12.90 billion in 2023.</p>\n<p>\\n\\nThe company positions MT1002 as a potential entrant into this sizeable market, with the ongoing clinical study intended to generate key safety and efficacy data to guide further development steps.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02335","symbol_name":"麦科医药-B","start_time":0,"source_url":"","article_id":"1102266225","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102266225","pubTimestamp":1783077882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02335":"麦科医药-B"},"translate_title":"Micot Pharma在MT1002治疗急性缺血性卒中的Ib/II期试验中招募首例患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1},"content_text":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute ischemic stroke (AIS), following the successful enrolment of the first patient.\n\\n\\nThe trial is structured in two sequential parts. Part 1 is a multicentre study designed to assess the safety, preliminary efficacy and pharmacokinetic profile of MT1002 in AIS patients. Part 2 will advance to a multicentre, randomised, standard-of-care–controlled design, focusing on broader safety and efficacy metrics. The initial patient enrolment announced pertains to Part 1.\n\\n\\nMarket data underscore the therapeutic need: AIS represents approximately 69.60%–72.80% of newly diagnosed strokes in China, according to “Advances in the Treatment of Acute Ischemic Stroke (2025)”. Pharnexcloud estimates place the Chinese market for acute-phase ischemic stroke therapies consistently above RMB10 billion in recent years, reaching RMB12.90 billion in 2023.\n\\n\\nThe company positions MT1002 as a potential entrant into this sizeable market, with the ongoing clinical study intended to generate key safety and efficacy data to guide further development steps.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102266225","isCrawlerRequest":true}